You just have to follow the increasingly extensive trail “Big Pharma” of in-licensing partnerships to Chinese companies to appreciate the scale of change. Not only does China innovate but it deploys rapidly at scale (by deploy I mean the acquisition of clinical data). Although China’s strength lies mostly in Oncology and in ADCs, I expect this to expand in time to cover Immunology. The caveat may be the quality of clinical data but we should have some idea of this in the next year or so.
I love the way you structured this post! Very informative.
Thank you Ruby. Fascinating as always.
You just have to follow the increasingly extensive trail “Big Pharma” of in-licensing partnerships to Chinese companies to appreciate the scale of change. Not only does China innovate but it deploys rapidly at scale (by deploy I mean the acquisition of clinical data). Although China’s strength lies mostly in Oncology and in ADCs, I expect this to expand in time to cover Immunology. The caveat may be the quality of clinical data but we should have some idea of this in the next year or so.